A groundbreaking partnership between University College London Hospitals NHS Foundation Trust (UCLH) and Guilford Street Laboratories (GSL) is set to transform diagnostic testing in the NHS. By integrating artificial intelligence, mass spectrometry, and clinical expertise, the collaboration will deliver earlier diagnoses, improved therapy monitoring, and better outcomes for conditions such as Parkinson’s disease, inherited metabolic disorders, and cardiovascular conditions.
Emerging therapies, including genetic and protein treatments, require highly sensitive diagnostics. This partnership leverages GSL’s advanced method development and biomarker expertise alongside UCLH’s Neurometabolic Unit, a leader in specialised clinical diagnostics.
Founded in 2024 as a UCL spinout, GSL combines the expertise of its founders – Professors Kevin Mills, Dr Tomas Baldwin, and Dr Wendy Heywood – with cutting-edge technology. “Together, we will discover new biomarkers and develop groundbreaking tests, accelerating translation into the NHS,” said Professor Mills.
Professor Simon Heales of UCLH added, “This collaboration ensures we remain at the forefront of diagnostics and translational research, delivering state-of-the-art care for patients.”
Read the full story here.
